Mark Bridge
YOU?
Author Swipe
View article: Supplementary Table 1 from Immune Modulation with RANKL Blockade through Denosumab Treatment in Patients with Cancer
Supplementary Table 1 from Immune Modulation with RANKL Blockade through Denosumab Treatment in Patients with Cancer Open
Characteristics of trial patients
View article: Supplementary Figure 5 from Immune Modulation with RANKL Blockade through Denosumab Treatment in Patients with Cancer
Supplementary Figure 5 from Immune Modulation with RANKL Blockade through Denosumab Treatment in Patients with Cancer Open
Supplementary Figure 5: Effects of concomitant treatments during denosumab treatment Heatmaps summarizing log2 fold changes from statistical analysis of functional markers CD137, CD27, CD40, CD40L, CD71, CD95, CTLA-4, HLA-DR, ICOS, Ki-67, …
View article: CD4+ CAR T-cell exhaustion associated with early relapse of multiple myeloma after BCMA CAR T-cell therapy
CD4+ CAR T-cell exhaustion associated with early relapse of multiple myeloma after BCMA CAR T-cell therapy Open
Multiple myeloma is characterized by frequent clinical relapses after conventional therapy. Recently, chimeric antigen receptor (CAR) T cells targeting B-cell maturation antigen (BCMA) has been established as a treatment option for patient…
View article: Supplementary Table 3 from Immune Modulation with RANKL Blockade through Denosumab Treatment in Patients with Cancer
Supplementary Table 3 from Immune Modulation with RANKL Blockade through Denosumab Treatment in Patients with Cancer Open
Supplementary Table 3: primer sequences
View article: Supplementary Figure 3 from Immune Modulation with RANKL Blockade through Denosumab Treatment in Patients with Cancer
Supplementary Figure 3 from Immune Modulation with RANKL Blockade through Denosumab Treatment in Patients with Cancer Open
Supplementary Figure 3: Expression of immune checkpoints at baseline (A) A uniform manifold approximation and projection (UMAP) plot of cells from all peripheral blood mononuclear cell (PBMC) samples analyzed with Scaffold using data from …
View article: Supplementary Figure 5 from Immune Modulation with RANKL Blockade through Denosumab Treatment in Patients with Cancer
Supplementary Figure 5 from Immune Modulation with RANKL Blockade through Denosumab Treatment in Patients with Cancer Open
Supplementary Figure 5: Effects of concomitant treatments during denosumab treatment Heatmaps summarizing log2 fold changes from statistical analysis of functional markers CD137, CD27, CD40, CD40L, CD71, CD95, CTLA-4, HLA-DR, ICOS, Ki-67, …
View article: Supplementary Table 1 from Immune Modulation with RANKL Blockade through Denosumab Treatment in Patients with Cancer
Supplementary Table 1 from Immune Modulation with RANKL Blockade through Denosumab Treatment in Patients with Cancer Open
Characteristics of trial patients
View article: Supplementary Figure 1 from Immune Modulation with RANKL Blockade through Denosumab Treatment in Patients with Cancer
Supplementary Figure 1 from Immune Modulation with RANKL Blockade through Denosumab Treatment in Patients with Cancer Open
Supplementary Figure 1: Manual gating strategy A representative patient sample was used to illustrate the gating strategy on Cytobank to create pre-determined landmark nodes for scaffold analysis and clustering.
View article: Supplementary Table 2 from Immune Modulation with RANKL Blockade through Denosumab Treatment in Patients with Cancer
Supplementary Table 2 from Immune Modulation with RANKL Blockade through Denosumab Treatment in Patients with Cancer Open
Supplementary Table 2
View article: Supplementary Figure 2 from Immune Modulation with RANKL Blockade through Denosumab Treatment in Patients with Cancer
Supplementary Figure 2 from Immune Modulation with RANKL Blockade through Denosumab Treatment in Patients with Cancer Open
Supplementary Figure 2: TREC and RANKL quantitation (A) Standard curves of tRNA were prepared on every reaction plate in triplicate for 100,000 to 12 TREC copies and β-actin. (B) Gene expression of RANKL in circulating immune cells was qua…
View article: Supplementary Figure 1 from Immune Modulation with RANKL Blockade through Denosumab Treatment in Patients with Cancer
Supplementary Figure 1 from Immune Modulation with RANKL Blockade through Denosumab Treatment in Patients with Cancer Open
Supplementary Figure 1: Manual gating strategy A representative patient sample was used to illustrate the gating strategy on Cytobank to create pre-determined landmark nodes for scaffold analysis and clustering.
View article: Supplementary Figure 3 from Immune Modulation with RANKL Blockade through Denosumab Treatment in Patients with Cancer
Supplementary Figure 3 from Immune Modulation with RANKL Blockade through Denosumab Treatment in Patients with Cancer Open
Supplementary Figure 3: Expression of immune checkpoints at baseline (A) A uniform manifold approximation and projection (UMAP) plot of cells from all peripheral blood mononuclear cell (PBMC) samples analyzed with Scaffold using data from …
View article: Supplementary Figure 2 from Immune Modulation with RANKL Blockade through Denosumab Treatment in Patients with Cancer
Supplementary Figure 2 from Immune Modulation with RANKL Blockade through Denosumab Treatment in Patients with Cancer Open
Supplementary Figure 2: TREC and RANKL quantitation (A) Standard curves of tRNA were prepared on every reaction plate in triplicate for 100,000 to 12 TREC copies and β-actin. (B) Gene expression of RANKL in circulating immune cells was qua…
View article: Supplementary Figure 4 from Immune Modulation with RANKL Blockade through Denosumab Treatment in Patients with Cancer
Supplementary Figure 4 from Immune Modulation with RANKL Blockade through Denosumab Treatment in Patients with Cancer Open
Supplementary Figure 4: Pre-existing immune condition prior to denosumab treatment Heatmaps summarizing log2 fold changes from statistical analysis of functional markers CD137, CD27, CD40, CD40L, CD71, CD95, CTLA-4, HLA-DR, ICOS, Ki-67, NK…
View article: Supplementary Figure 4 from Immune Modulation with RANKL Blockade through Denosumab Treatment in Patients with Cancer
Supplementary Figure 4 from Immune Modulation with RANKL Blockade through Denosumab Treatment in Patients with Cancer Open
Supplementary Figure 4: Pre-existing immune condition prior to denosumab treatment Heatmaps summarizing log2 fold changes from statistical analysis of functional markers CD137, CD27, CD40, CD40L, CD71, CD95, CTLA-4, HLA-DR, ICOS, Ki-67, NK…
View article: Supplementary Table 2 from Immune Modulation with RANKL Blockade through Denosumab Treatment in Patients with Cancer
Supplementary Table 2 from Immune Modulation with RANKL Blockade through Denosumab Treatment in Patients with Cancer Open
Supplementary Table 2
View article: Supplementary Table 3 from Immune Modulation with RANKL Blockade through Denosumab Treatment in Patients with Cancer
Supplementary Table 3 from Immune Modulation with RANKL Blockade through Denosumab Treatment in Patients with Cancer Open
Supplementary Table 3: primer sequences
View article: Supplementary Figure 1 from Immune Modulation with RANKL Blockade through Denosumab Treatment in Patients with Cancer
Supplementary Figure 1 from Immune Modulation with RANKL Blockade through Denosumab Treatment in Patients with Cancer Open
Supplementary Figure 1: Manual gating strategy A representative patient sample was used to illustrate the gating strategy on Cytobank to create pre-determined landmark nodes for scaffold analysis and clustering.
View article: Supplementary Figure 4 from Immune Modulation with RANKL Blockade through Denosumab Treatment in Patients with Cancer
Supplementary Figure 4 from Immune Modulation with RANKL Blockade through Denosumab Treatment in Patients with Cancer Open
Supplementary Figure 4: Pre-existing immune condition prior to denosumab treatment Heatmaps summarizing log2 fold changes from statistical analysis of functional markers CD137, CD27, CD40, CD40L, CD71, CD95, CTLA-4, HLA-DR, ICOS, Ki-67, NK…
View article: Supplementary Table 2 from Immune Modulation with RANKL Blockade through Denosumab Treatment in Patients with Cancer
Supplementary Table 2 from Immune Modulation with RANKL Blockade through Denosumab Treatment in Patients with Cancer Open
Supplementary Table 2
View article: Data from Immune Modulation with RANKL Blockade through Denosumab Treatment in Patients with Cancer
Data from Immune Modulation with RANKL Blockade through Denosumab Treatment in Patients with Cancer Open
Denosumab is a fully human mAb that binds receptor activator of NFκB ligand (RANKL). It is routinely administered to patients with cancer to reduce the incidence of new bone metastasis. RANK–RANKL interactions regulate bone turnover by con…
View article: Data from Immune Modulation with RANKL Blockade through Denosumab Treatment in Patients with Cancer
Data from Immune Modulation with RANKL Blockade through Denosumab Treatment in Patients with Cancer Open
Denosumab is a fully human mAb that binds receptor activator of NFκB ligand (RANKL). It is routinely administered to patients with cancer to reduce the incidence of new bone metastasis. RANK–RANKL interactions regulate bone turnover by con…
View article: Supplementary Table 2 from Immune Modulation with RANKL Blockade through Denosumab Treatment in Patients with Cancer
Supplementary Table 2 from Immune Modulation with RANKL Blockade through Denosumab Treatment in Patients with Cancer Open
Supplementary Table 2
View article: Supplementary Table 3 from Immune Modulation with RANKL Blockade through Denosumab Treatment in Patients with Cancer
Supplementary Table 3 from Immune Modulation with RANKL Blockade through Denosumab Treatment in Patients with Cancer Open
Supplementary Table 3: primer sequences
Supplementary Figure 2 from Immune Modulation with RANKL Blockade through Denosumab Treatment in Patients with Cancer Open
Supplementary Figure 2: TREC and RANKL quantitation (A) Standard curves of tRNA were prepared on every reaction plate in triplicate for 100,000 to 12 TREC copies and -actin. (B) Gene expression of RANKL in circulating immune cells was qua…
Supplementary Table 1 from Immune Modulation with RANKL Blockade through Denosumab Treatment in Patients with Cancer Open
Characteristics of trial patients
Supplementary Figure 2 from Immune Modulation with RANKL Blockade through Denosumab Treatment in Patients with Cancer Open
Supplementary Figure 2: TREC and RANKL quantitation (A) Standard curves of tRNA were prepared on every reaction plate in triplicate for 100,000 to 12 TREC copies and -actin. (B) Gene expression of RANKL in circulating immune cells was qua…
Supplementary Figure 4 from Immune Modulation with RANKL Blockade through Denosumab Treatment in Patients with Cancer Open
Supplementary Figure 4: Pre-existing immune condition prior to denosumab treatment Heatmaps summarizing log2 fold changes from statistical analysis of functional markers CD137, CD27, CD40, CD40L, CD71, CD95, CTLA-4, HLA-DR, ICOS, Ki-67, NK…
Supplementary Figure 1 from Immune Modulation with RANKL Blockade through Denosumab Treatment in Patients with Cancer Open
Supplementary Figure 1: Manual gating strategy A representative patient sample was used to illustrate the gating strategy on Cytobank to create pre-determined landmark nodes for scaffold analysis and clustering.
Supplementary Table 1 from Immune Modulation with RANKL Blockade through Denosumab Treatment in Patients with Cancer Open
Characteristics of trial patients